HCAR 2
Alternative Names: HCAR-2Latest Information Update: 28 Mar 2024
At a glance
- Originator ImmunoACT
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 19 Mar 2024 ImmunoACT plans a pivotal phase II trial for Multiple myeloma (Second-line therapy or greater) in 2026 (Parenteral) (Immunoact pipeline, March 2024)
- 19 Mar 2024 Preclinical trials in Multiple myeloma in India (Parenteral), prior to March 2024 (ImmunoACT pipeline, March 2024)
- 12 Feb 2019 ImmunoACT has patents pending for HCAR 2 in World